- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01857986
Evaluating Air Leak Detection in Intubated Patients
A Study to Evaluate Air Leak Detection Above the Endotracheal Cuff in Intubated Patients Using the AnapnoGuard 100 System
This trial is designed to assess the effectiveness of the AnapnoGaurd 100 system relative to standard of care (SOC) Control, in the course of mechanical ventilation and intubation. The main effectiveness aspect of this trial is the AnapnoGaurd 100's ability to reduce leaks between the endotracheal tube and the trachea walls as a result of the cuff pressure management. Since the primary outcome can't be measured by any method other than the investigational device, the study groups will be treated as follows:
- The Treatment group in this study will be treated with the fully functional AnapnoGaurd 100 device (per its intended use),
- The Control group will be treated with the AnapnoGuard device, where the cuff control will be disabled (off) and the cuff management will be done according to SOC.
Effectiveness will be measured by the duration and level of carbon dioxide (CO2) leakage around the endotracheal tube (ETT) cuff, from the lungs to the subglottic space and safety will be measured by adverse events (AEs).
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Bnei Brak, Israel
- Mayanei Hayeshua Medical Center, General ICU
-
Haifa, Israel
- Rambam Medical Center, Cardiac Surgery Department
-
Haifa, Israel
- Rambam Medical Center, Neurosurgery Department
-
Holon, Israel
- Wolfson Medical Center, General ICU
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age above 18 (men and women);
- Subject is expected to receive mechanical ventilation for more than 12 hours;
- Connection of the ETT to the AnapnoGuard system within 12 hours from intubation initiation;
- Subject or subject's legally acceptable representative signed the Informed Consent Form
Exclusion Criteria:
1. Subjects with facial, oropharyngeal or neck trauma 2. BMI>40 3. Pregnant women 4. Patient ventilated in prone position 5. Difficult intubation (defined as more than 3 intubation attempts)
-
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Study group
Subjects in the study group will be connected to the AnapnoGuard 100 control unit operating in the normal clinical mode (automatic CO2 leak measurement above the cuff, cuff pressure control, evacuation of secretions and tracheal rinsing)
|
|
Active Comparator: Control group
Subjects in the control group will be connected to the AnapnoGuard 100 control unit.
In the control group, the cuff pressure control of the AnapnoGuard 100 control unit will be disabled (OFF).
CO2 level above the cuff will be recorded.
Suction and rinsing function will operate after the system detects no CO2.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
CO2 Leakage Above the ETT Cuff, Measured Over Time.
Time Frame: Subjects will be followed for the duration of endotracheal intubation, an expected average of 4 days
|
Trial outcome measure represents patients' exposure to CO2 leakage standardized per hour. Specifically, each patients' area under the curve (AUC) of CO2 leakage (mmHg) is computed over the whole trial by multiplying leakage duration (X-axis; continuous time) by CO2 level (Y-axis; mmHg), divided by the patient's number of hours in the trial. Outcome measure is thus [CO2 mmHg*hour]/hour. CO2 leakage is the concentration of CO2 above the cuff as measured by the AG100 system every few minutes (in clinical mode). Time points which created the curve were every two adjacent time intervals having a valid CO2 reading. |
Subjects will be followed for the duration of endotracheal intubation, an expected average of 4 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of the Cuff Pressure Measurements Within the Safety Accepted Range (24 and 40cmH2O)
Time Frame: Subjects will be followed for the duration of endotracheal intubation, an expected average of 4 days
|
mean number of cuff pressure measurements within the safety accepted range of 24 and 40 cmH2O, normalized using the total number of valid cuff pressure measurements.
|
Subjects will be followed for the duration of endotracheal intubation, an expected average of 4 days
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Shai Efrati, MD, Hospitech Respiration
- Principal Investigator: Gil Bolotin, MD
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- HST-AG-07
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Critical Care
-
Potrero MedicalCompletedCritical Care, Intensive Care
-
Hospital Israelita Albert EinsteinActive, not recruitingCritical Care | Intensive Care UnitBrazil
-
University College, LondonCompleted
-
Hospital do CoracaoD'Or Institute for Research and Education; Sociedade Hospital SamaritanoCompleted
-
Hospital Israelita Albert EinsteinMinistry of Health, BrazilNot yet recruitingTelemedicine | Critical Care | Intensive Care Units
-
Hospital Nossa Senhora da ConceicaoRecruiting
-
Hospices Civils de LyonRecruiting
-
University Hospital, ToursCompleted
-
Centre Hospitalier Universitaire de BesanconCompleted
-
InLight SolutionsLuminous MedicalCompletedCritical CareUnited States
Clinical Trials on AnapnoGuard 100 control unit
-
Hospitech RespirationCompletedVentilator Associated PneumoniaRomania
-
Hospitech RespirationCompleted
-
Hospitech RespirationCompletedVentilator Associated PneumoniaIsrael
-
Dartmouth-Hitchcock Medical CenterPatient-Centered Outcomes Research Institute; University of Alabama at Birmingham and other collaboratorsRecruitingOveractive Bladder | Urinary Incontinence in Old Age | Urgency Urinary IncontinenceUnited States
-
Corporacion Parc Tauli3MCompleted
-
VA Office of Research and DevelopmentRecruitingUrinary Incontinence | Urinary Bladder, NeurogenicUnited States
-
Sheba Medical CenterUnknownBrain Ischemia | Child | Congenital Heart Defects | Hypothermia, Induced | Hypoxia Brain
-
Fate TherapeuticsCompletedChronic Lymphocytic Leukemia (CLL) | Acute Lymphoblastic Leukemia (ALL) | Non-Hodgkin's Lymphoma (NHL) | Hodgkin's Disease | Acute Myelogenous Leukemia (AML)United States
-
Pyramid BiosciencesCompletedHealthy VolunteersUnited States
-
A.T. Still University of Health SciencesCompleted